Russian drug spending set to reach US$4 billion by 2020

Home/Policies & Legislation | Posted 07/07/2010 post-comment0 Post your comment

Russia is planning to pump RUB 120 billion (US$4 billion) into its fledgling pharmaceutical sector this decade as part of a broader push to diversify the economy away from its traditional oil and gas industry.

picture30

"The development of Russian pharmaceuticals will not go through without help from the state” stated Industry Minister, Mr Viktor Khristenko.

Under its strategy for pharmaceutical sector development, Russia aims to increase local producers' share of total drug sales from its current 20% to 25% by 2012 and 50% by 2020.

The Russian government's plans include a range of incentives for locally-made products, such as faster registration and preferred status in the programme which supplies health care to those on low incomes.

According to the Russian Association of International Pharmaceutical Manufacturers, global drugmakers are ready to spend a combined US$1 billion on setting up local production in Russia. Multinationals which have announced plans to set up or extend manufacturing facilities in Russia, include AstraZeneca, GlaxoSmithKline, Novartis, Novo Nordisk, Pfizer, and Sanofi-aventis.

With growth in the Russian pharmaceutical market set to far outpace that for western nations and sales this year expected to grow by RUB 12% and US$ 18–20% this is looking like a very lucrative market.

By 2010, the Russian pharmaceutical market should be worth at least US$60 billion, and could rise as high as US$90 billion, according to Pharmexpert.

References:

Reuters Article, Russia to spend $4 billion on pharma industry by 2020, 19 June 2010

Russian Association of International Pharmaceutical Manufacturers (AIPM) [homepage on the Internet]. Moscow, Russia: AIPM; c1994-2009 [cited 2010 June 22].

Pharmexpert, Main trends of Russia’s pharma market [page on the Internet]. Moscow, Russia: Pharmexpert; c1994-2009 [updated 2010 May 11; cited 2010 June 22].

comment icon Comments (0)
Post your comment
Related content
PDUFA VI: FDA could promote generics competition
47 MD001813
Home/Policies & Legislation Posted 29/07/2022
House bill passes FDA funding fees but conflicts with Senate bill
User Fee V13H23
Home/Policies & Legislation Posted 15/07/2022
US Senate clarifies status of interchangeable biosimilar exclusivity
Interchangeability V18K30
Home/Policies & Legislation Posted 27/05/2022
Nomenclature of biologicals and biosimilars in Peru
02 AA010638
Home/Policies & Legislation Posted 20/05/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010